Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat [Seeking Alpha]
Structure Therapeutics Inc. (GPCR)
Company Research
Source: Seeking Alpha
Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario. Phase 3 Aleniglipron trial is the key catalyst, with a modeled 67.7% probability of success and potential $6B peak global sales. Looking for a portfolio of ideas like this one? Members of Vasuda Healthcare Analytics get exclusive access to our subscriber-only portfolios. Learn More » digicomphoto/iStock via Getty Images EQUITY RESEARCH | BIOTECHNOLOGY | INITIATING COVERAGE Structure Therapeutics ( GPCR RATING: BUY PT: $110 PRICE: $54.68 UPSIDE: +101% Click to enlarge Market Cap $3.8B | Cash $1.4B | Runway Through 2028 | Shares 60.6M ADSs | Sector: Metabolic / Obesity More on my IG service Premium service reviews "The best I have ever seen in the biotech space...I have been in the biotech invest
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics Phase 2 Obesity Data Shifts Focus To Phase 3 [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics (GPCR) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GPCR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- Structure Therapeutics (GPCR) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Structure Therapeutics CEO on the company's oral GLP-1 opportunity [CNBC]CNBC
- Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges [Yahoo! Finance]Yahoo! Finance
GPCR
Sec Filings
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- GPCR's page on the SEC website